Improved arthropathy scores after use of Extended Half-Life (EHL) products in prophylactic treatment of adult patients with Haemophilia A & B

被引：0
|
作者：
Christidi, Styliani-Despoina [1 ]
Thevaeos, George [1 ]
Zannou, Anna [2 ,3 ]
Vlahopoulou, Dimitra [2 ,3 ]
Veziris, George [1 ]
Gavalaki, Maria [2 ,3 ]
Kourampa, Anna [2 ,3 ]
机构：
[1] Laikon Gen Hosp, Dept Orthoped, Athens, Greece
[2] Blood Transfus Ctr, Athens, Greece
[3] Natl Reference Ctr Congenital Bleeding Disorders, Athens, Greece
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
Haemophilia; Extended Half-Life (EHL); HJHS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-040
引用
收藏
页码：38 / 39
页数：2
相关论文
共 50 条
  • [21] Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
    Iorio, Alfonso
    Fischer, Kathelijn
    Blanchette, Victor
    Rangarajan, Savita
    Young, Guy
    Marfini, Massimo
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (06) : 1023 - 1030
  • [22] Real-life experience in switching to new extended half-life products at European haemophilia centres
    Peyvandi, Flora
    Garagiola, Isabella
    Boscarino, Marco
    Ryan, Aislin
    Hermans, Cedric
    Makris, Michael
    HAEMOPHILIA, 2019, 25 (06) : 946 - 952
  • [23] Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products
    Tortella, Bartholomew J.
    Alvir, Jose
    McDonald, Margaret
    Spurden, Dean
    Fogarty, Patrick F.
    Chhabra, Amit
    Pleil, Andreas M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 643 - 653
  • [24] MAJOR ORTHOPEDIC SURGERIES USING EXTENDED HALF-LIFE (EHL) COAGULATION REPLACEMENT FACTORS: THE EXPERIENCE OF A GREEK COMPREHENSIVE HAEMOPHILIA TREATMENT CENTER (CHTC)
    Kouramba, A.
    Georgopoulou, A. N.
    Zannou, A.
    Kosmas, P.
    Galopoulos, D.
    Chatzidavid, S.
    Christidi, S.
    Thivaios, G. C.
    HAEMOPHILIA, 2022, 28 : 69 - 70
  • [25] CLINICAL APPLICATION OF EXTENDED HALF-LIFE FACTOR VIII AND IX IN CHILDREN WITH HAEMOPHILIA A AND B
    Dettoraki, A.
    Michalopoulou, A.
    Saslis, S.
    Kapsimali, Z.
    Mazarakis, M.
    Thymianou, S.
    Stamati, I.
    Pergantou, H.
    HAEMOPHILIA, 2021, 27 : 53 - 54
  • [26] Use of extended half-life Factor VIII and IX concentrates in haemophilia: a clinical audit
    Elder, P.
    Bailiff, B.
    Marshall, K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 191 - 192
  • [27] Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates
    von Mackensen, S.
    Kalnins, W.
    Krucker, J.
    Weiss, J.
    Miesbach, W.
    Albisetti, M.
    Pabinger, I.
    Oldenburg, J.
    HAEMOPHILIA, 2017, 23 (04) : 566 - 574
  • [28] EXTENDED HALF-LIFE (EHL) RECOMBINANT FACTOR VIII (RFVIII) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY: COST OF TREATMENT COMPARISON
    Demma, F.
    Di Martino, G.
    VALUE IN HEALTH, 2021, 24 : S203 - S203
  • [29] LongHest project: A prospective, observational study of extended half-life treatment in the musculoskeletal health of patients with severe haemophilia A
    Cuesta-Barriuso, Ruben
    Perez-Llanes, Raul
    Donoso-Ubeda, Elena
    Ucero-Lozano, Roberto
    HAEMOPHILIA, 2022, 28 (05) : 857 - 864
  • [30] The costs and benefits of extended half-life clotting factors in patients with severe haemophilia A at a single institution
    Hou, J. -Y.
    Liu, H. -C.
    Yeh, T. -C.
    Huang, T. -H.
    Lew, C. -Z.
    Cheng, C. -Y.
    HAEMOPHILIA, 2024, 30 : 71 - 71
12345